Abstract
Microtubule assembly and disassembly is required for the maintenance of cell structure, mobility, and division. However, the cellular and biochemical implications of microtubule disruption are not fully understood. Using a proteomic approach, we found that the peptidyl-prolyl isomerase, cyclophilin A, was increased in plasma membrane extracts from chronic myeloid leukemia cells after microtubule disruption. In addition, we found that two peptidyl-prolyl isomerases, cyclophilin A and pin1, are overexpressed up to 10-fold in hematological malignancies compared with normal peripheral blood mononuclear cells. Although previous reports suggest that cyclophilin A is localized to the cytosol of mammalian cells, we found that cyclophilin A and pin1 are both localized to the nucleus and nuclear domains in hematopoietic cells. Microtubule disruption of hematopoietic cells caused a dramatic subcellular redistribution of cyclophilin A and pin1 from the nucleus to the cytosol and plasma membrane. We suggest that this accounts for the increased cyclophilin A at the plasma membrane of chronic myeloid leukemia cells after microtubule disruption. The subcellular redistribution of cyclophilin A and pin1 occurred in a c-Jun NH2-terminal kinase- and serine protease-dependent manner. Moreover, the altered subcellular localization of the peptidyl-prolyl isomerases occurred in a dose- and time-dependent manner after microtubule disruption and was found to correlate with G2/M arrest and precede induced cell death. These results suggest that the function of peptidyl-prolyl isomerases may be influenced by microtubule dynamics throughout the cell cycle, and their altered localization may be an important part of the mechanism by which microtubule-disrupting agents exert their cytostatic effects.
Footnotes
-
This work was supported by The Irish Council for Science, Engineering and Technology; The Health Research Board, Ireland; University College Dublin Seed Funding; and the Irish Higher Education Authority (PRTLI).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.108.148130
-
ABBREVIATIONS:
- CML
- chronic myeloid leukemia
- MTA
- microtubule-targeting agent
- PBOX-6
- pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine
- JNK
- c-Jun NH2-terminal kinase
- PPIase
- peptidyl-prolyl isomerase
- PAGE
- polyacrylamide gel electrophoresis
- MALDI-TOF
- matrix-assisted laser desorption ionization/time of flight
- cypA
- cyclophilin A
- TPCK
- N-tosyl-l-phenylalanine chloromethyl ketone
- TLCK
- N-tosyl-l-lysine chloromethyl ketone
- ECL
- enhanced chemiluminescence
- FCS
- fetal calf serum
- PBS
- phosphate-buffered saline
- ACN
- acetonitrile
- PBMC
- peripheral blood mononuclear cell
- TBS
- Tris-buffered saline
- TBST
- Tris-buffered saline/Tween 20
- BSA
- bovine serum albumin
- DAPI
- 4,6-diamidino-2-phenylindole
- GR
- glucocorticoid receptor.
- Received October 30, 2008.
- Accepted January 7, 2009.
- © 2009 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|